Abstract
Anhedonia, characterized by a loss of interest and/or pleasure in previously enjoyable activities, is an important diagnostic criterion of Major Depressive Disorder (MDD). Converging evidence implicates a causal relationship between proinflammatory cytokines and behavioural disturbances that characterize anhedonia in the context of MDD. Additionally, anhedonia has been implicated in disturbances of key central dopaminergic modulatory pathways. Emerging research into the roles of tetrahydrobiopterin, a cytokine-targeted co-enzyme in the synthesis of dopamine, and kynurenine, a product of inflammation-sensitive breakdown of tryptophan via indoleamine 2, 3-dioxygenase, have shed new light into the role of inflammation in mediating anhedonic behaviours. The following narrative review is not meant to be comprehensive, but highlights the roles of both tetrahydrobiopterin and kynurenine pathways in anhedonia, and discusses a potential mechanism of action via oxidative stress and excitotoxicity. Treatment implications are discussed, with an emphasis on anti-inflammatories as complements to current treatments of anhedonia and MDD.
Keywords: Anhedonia, Major Depressive Disorder (MDD), inflammation, tetrahydrobiopterin, kynurenine pathway, cytokines, oxidative stress, treatment implications.
Current Pharmaceutical Design
Title:Role of Proinflammatory Cytokines in Dopaminergic System Disturbances, Implications for Anhedonic Features of MDD
Volume: 23 Issue: 14
Author(s): Zihang Pan, Joshua D. Rosenblat, Walter Swardfager and Roger S. McIntyre*
Affiliation:
- Professor of Psychiatry and Pharmacology, University of Toronto, Head, Mood Disorders Psychopharmacology Unit, University Health Network, 399 Bathurst Street - Toronto, ON,Canada
Keywords: Anhedonia, Major Depressive Disorder (MDD), inflammation, tetrahydrobiopterin, kynurenine pathway, cytokines, oxidative stress, treatment implications.
Abstract: Anhedonia, characterized by a loss of interest and/or pleasure in previously enjoyable activities, is an important diagnostic criterion of Major Depressive Disorder (MDD). Converging evidence implicates a causal relationship between proinflammatory cytokines and behavioural disturbances that characterize anhedonia in the context of MDD. Additionally, anhedonia has been implicated in disturbances of key central dopaminergic modulatory pathways. Emerging research into the roles of tetrahydrobiopterin, a cytokine-targeted co-enzyme in the synthesis of dopamine, and kynurenine, a product of inflammation-sensitive breakdown of tryptophan via indoleamine 2, 3-dioxygenase, have shed new light into the role of inflammation in mediating anhedonic behaviours. The following narrative review is not meant to be comprehensive, but highlights the roles of both tetrahydrobiopterin and kynurenine pathways in anhedonia, and discusses a potential mechanism of action via oxidative stress and excitotoxicity. Treatment implications are discussed, with an emphasis on anti-inflammatories as complements to current treatments of anhedonia and MDD.
Export Options
About this article
Cite this article as:
Pan Zihang, Rosenblat D. Joshua, Swardfager Walter and McIntyre S. Roger*, Role of Proinflammatory Cytokines in Dopaminergic System Disturbances, Implications for Anhedonic Features of MDD, Current Pharmaceutical Design 2017; 23 (14) . https://dx.doi.org/10.2174/1381612823666170111144340
DOI https://dx.doi.org/10.2174/1381612823666170111144340 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Rabbit Syndrome: State of the Art
Current Clinical Pharmacology Functional Food with Some Health Benefits, So Called Superfood: A Review
Current Nutrition & Food Science Demonstration of Biological and Immunological Equivalence of a Generic Glatiramer Acetate
CNS & Neurological Disorders - Drug Targets Inhibition of RNA Virus Infections with Peptide-Conjugated Morpholino Oligomers
Current Pharmaceutical Design FGF21 and its Relationship with Inflammatory and Metabolic Parameters in HIV Patients after Antiretroviral Treatment
Current HIV Research Comparison of Pharmacodynamics and Celiac Effects of Olmesartan Medoxomil Formulations by using Olmesartan-induced Celiac-rat-model
Current Drug Delivery Interaction between Thienopyridines and Proton Pump Inhibitors
Cardiovascular & Hematological Disorders-Drug Targets Anti-Inflammatory Approaches that Target the Chemokine Network
Recent Patents on Inflammation & Allergy Drug Discovery Inhibition of Human Phenol and Estrogen Sulfotransferase by Certain Non-Steroidal Anti-Inflammatory Agents
Current Drug Metabolism From Cannabis to Endocannabinoids in Multiple Sclerosis: A Paradigm of Central Nervous System Autoimmune Diseases
Current Drug Targets - CNS & Neurological Disorders Blocking HIV-1 Replication by Targeting the Tat-Hijacked Transcriptional Machinery
Current Pharmaceutical Design Novel Structural Hybrids on the Base of Benzofuroxans and Furoxans. Mini-Review
Current Topics in Medicinal Chemistry Drug-Induced Pulmonary Hypertension in Newborns: A Review.
Current Vascular Pharmacology Identifying the Cellular Targets of Bioactive Small Molecules with Activity-Based Probes
Current Medicinal Chemistry Possible Targets of Herbals for Type 3 Diabetes: A Review
Current Traditional Medicine The Plasticity of the 7TMR Signaling Machinery and the Search for Pharmacological Selectivity
Current Pharmaceutical Design Transient Receptor Potential A1 Modulators
Current Topics in Medicinal Chemistry Steroid Receptor-Associated Immunophilins: Candidates for Diverse Drug-Targeting Approaches in Disease
Current Molecular Pharmacology Preface
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Patent Selections
Recent Patents on Inflammation & Allergy Drug Discovery